Affiliation:
1. Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA.
Abstract
The activities of the water-soluble pneumocandin derivatives L-733560, L-705589, and L-731373 were evaluated in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis and were compared with those of commercially available antifungal agents. Pneumocandins are inhibitors of 1,3-beta-D-glucan synthesis. In the aspergillosis model, L-733560 and L-705589 significantly prolonged the survival of DBA/2N mice challenged intravenously with Aspergillus fumigatus conidia. L-733560 and L-705589 exhibited efficacies comparable to that of amphotericin B (AMB) with 90% effective doses of 0.48, 0.12, and 0.36 mg/kg of body weight, respectively. Two mouse models of disseminated candidiasis were used to evaluate these compounds. In both models, mice were challenged intravenously with Candida albicans. In a C. albicans survival model with DBA/2N and CD-1 mice, the efficacy of L-733560 was comparable to that of AMB, while L-731373 and L-705589 were somewhat less active. In a previously described C. albicans target organ kidney assay, the pneumocandin analogs and AMB at doses of > or = 0.09 mg/kg were effective in sterilizing kidneys, while fluconazole and ketoconazole were considerably less active and did not sterilize kidneys when they were used at concentrations of < or = 100 mg/kg. Although orally administered L-733560 showed activity in both candidiasis models, its efficacy was reduced compared with that of parenterally administered drug. In a disseminated cryptococcosis mouse model that measures the number of CFU of Cryptococcus neoformans per gram of brain and spleen, L-733560 at 10 mg/kg was ineffective in reducing the counts in organs, while AMB at 0.31 mg/kg sterilized the organs. These results indicate that the pneumocandins may be beneficial as potent parenterally administered therapeutic agents for disseminated aspergillosis and candidiasis.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference28 articles.
1. Abruzzo G. K. A. Flattery C. Gill J. Smith H. Kropp and K. Bartizal. 1993. Evaluation of water soluble lipopeptides in a mouse model of disseminated aspergillosis abstr. 355 p. 184. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
2. Pneumocandin antifungal lipopeptides. The phenolic hydroxyl is required for 1,3-~-D-glucan synthesis inhibition;Balkovec J. M.;Bioorg. Med. Chem. Lett.,1993
3. Bartizal K. G. Abruzzo and D. Schmatz. 1993. The pneumocandins: biological activity of the pneumocandins p. 421-455. In J. Rippon and R. A. Fromtling (ed.) Cutaneous fungal infections. Marcel Dekker Inc. New York.
4. In vitro antifungal activities and in vivo efficacies of 1,3-~-D-glucan synthesis inhibitors L-671329, L-646991, tetrahydroechinocandin B, and L-687781, a papulacandin;Bartizal K.;Antimicrob. Agents Chemother.,1992
5. Bartizal K. G. K. Abruzzo A. M. Flattery C. J. Gill J. G. Smith L. Lynch C. Pacholok T. Scott L. Kong D. Krupa and H. Kropp. 1993. Anti-Candida in vivo efficacy of water soluble lipopeptides L-705589 L-731373 and L-733560 abstr. 353 p. 184. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献